BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18563366)

  • 1. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans.
    Baek IH; Yun MH; Yun HY; Kwon KI
    Arch Pharm Res; 2008 Jun; 31(6):814-21. PubMed ID: 18563366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
    Liu XY; Wang BJ; Yuan GY; Guo RC
    Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
    Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unpredicted lack of effect of exercise on plasma concentrations of carvedilol.
    Stoschitzky K; Zweiker R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
    J Cardiovasc Pharmacol; 2002 Jan; 39(1):58-60. PubMed ID: 11743228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
    Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
    Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
    Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
    Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
    Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.
    Huang XH; Li J; Qiu FR; Xie HT; Huang JH; Li JC; Zheng QS
    Eur J Drug Metab Pharmacokinet; 2006; 31(4):259-64. PubMed ID: 17315536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
    Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
    Stout SM; Nielsen J; Bleske BE; Shea M; Brook R; Kerber K; Welage LS
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):373-9. PubMed ID: 20705902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
    Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
    Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol.
    Wei L; Sun P; Nie S; Pan W
    Drug Dev Ind Pharm; 2005 Sep; 31(8):785-94. PubMed ID: 16221613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
    Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
    Kim MS; Baek IH
    Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
    Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
    Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol and atenolol once daily in the treatment of hypertension.
    Luurila OJ; Härkönen R; Hilden M; Icen R; Kohvakka A; Linna M; Sillanpää J; Vänskä O; Lukkala K
    J Hypertens Suppl; 1989 Dec; 7(6):S264-5. PubMed ID: 2576666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry.
    Poggi JC; Da Silva FG; Coelho EB; Marques MP; Bertucci C; Lanchote VL
    Chirality; 2012 Mar; 24(3):209-14. PubMed ID: 22271587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.